Canopy featured in the St. Louis Business Journal! Read all about us here.
“Canopy Biosciences, a young startup looking to accelerate the commercialization of life science reagent tools and services, has raised $2 million from investors.”
Canopy looks to in-license — essentially a collaboration agreement between two parties in which one company performs the R&D — technologies in the fields of genetic engineering and personalized medicine.
Smoller is a general partner at St. Louis venture capital firm Cultivation Capital and a board member with several local startups. Weinstein was previously president of Horizon Discovery, a United Kingdom translational genomics company, and is an entrepreneur-in-residence with the BioGenerator locally.
“The goal is to get these technologies funded by angel (investors), and to find the research tools and bring them together to form one tools company,” Smoller said. “There are a lot of products out there that don’t necessarily need to be their own companies, but need to be consolidated.”